How does cosentyx impact vaccine efficacy in non responders?

How long does the effect of Cosentyx on vaccine responses last?
Cosentyx blocks IL-17A, a cytokine that helps coordinate immune cell activity. Blocking it can dampen the production of protective antibodies after some vaccines, and this reduced response can persist for the duration of treatment. Patients who remain on Cosentyx continue to show lower antibody levels in follow-up blood tests months after vaccination compared with people not taking the drug.

What happens if someone stops Cosentyx before getting vaccinated?
Discontinuing Cosentyx several weeks before vaccination may allow partial recovery of IL-17A signaling. Small studies suggest antibody titers improve when the drug is paused, but full restoration of normal vaccine response is not guaranteed and varies by individual immune status.

Do patients on Cosentyx who fail to respond to one vaccine also fail others?
Non-responders to one vaccine, such as hepatitis B or pneumococcal, often show reduced responses to additional vaccines while on Cosentyx. The shared mechanism—impaired T-helper cell support—explains why the same patients tend to produce lower antibody levels across multiple vaccine types.

Can a different vaccine schedule or higher dose overcome the reduced response?
Some clinicians try extra doses or altered timing, yet data remain limited. Higher-dose influenza or repeated pneumococcal shots have produced only modest gains in antibody levels for patients taking IL-17 inhibitors. No standardized alternative schedule has been proven to restore full protection.

Are biosimilars of Cosentyx expected to have the same vaccine effect?
Any approved biosimilar of secukinumab will carry the same IL-17A blockade and therefore the same potential to blunt vaccine responses. Regulatory filings for these products reference the original clinical data rather than new vaccine studies.

When does the Cosentyx patent expire, and does that change vaccine guidance?
The primary U.S. composition-of-matter patent for secukinumab expires in 2029, with extensions possible. Until then, no interchangeable biosimilar is expected, so current vaccine counseling for Cosentyx users will likely remain unchanged.

[1] https://www.drugpatentwatch.com/drug/Cosentyx